SecBot SecBot

VYGR

Voyager Therapeutics, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001640266 Biotech & Drug Discovery
$1.75 +0.01 (+0.57%)
Oct 26 4:00 PM ET · prev $1.74
Market cap
$114.6M
Micro cap
Consensus
Buy
94% Buy or better · 17 analysts
Median target
$12.00
+586% · range $8.00–25.00
Next earnings
Nov 10
in 14 days · EPS est. −$0.42
1 year
−63.6%
from $4.81 · Oct 27
30 days
−35.2%
from $2.70
52-week range
$1.74–5.00
−65% from high · low Oct 23
Avg volume 20D
962.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
−$298.0K
0 buyers · 4 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read MIXED 1 report · 90 days
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 10, 2026
Strongest NEUTRAL Voyager Therapeutics promoted Robin Swartz from COO/CBO to President, effective October 20, 2026, with a…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $298.0K.

  • InstitutionsBULLISH

    Q2 2026: 18 added (0 new), 8 trimmed or exited.

  • AnalystsBULLISH

    16 of 17 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.475 → −$0.418 over 90 days. 3 up, 0 down in 30 days.

  • TrendDOWNTREND

    38% below its 50-day average. New closing low $1.74 on Oct 23.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
MILLENNIUM MANAGEMENT LLCADD4,442,951$15.6M
GEODE CAPITAL MANAGEMENT, LLCADD1,330,492$4.7M
CITADEL ADVISORS LLCDOUBLED784,067$2.7M
Erste Asset Management GmbHTRIM638,900$2.3M
Qube Research & Technologies LtdDOUBLED194,049$679.2K
PRICE T ROWE ASSOCIATES INC /MD/ADD155,526$545.0K
D. E. Shaw & Co., Inc.ADD143,992$504.0K
DEUTSCHE BANK AG\ADD51,293$179.5K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

17 analysts
Buy 94% rate it Buy or better
Strong Buy8Buy8Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +586%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Aug 10, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy

Insider ledger

Form 4
$0
bought · 0 insiders
$298.0K
sold · 4 insiders
DateInsiderTypeValue
Jun 9, 2026
PIERCE GLENN
Director
AWARD30,000 sh
Jun 9, 2026
Colon Grace
Director
AWARD30,000 sh
Jun 9, 2026
GERAGHTY JAMES A
Director
AWARD30,000 sh
Jun 9, 2026
Onyia Jude
Director
AWARD30,000 sh
Jun 9, 2026
Higgins Michael J
Director
AWARD30,000 sh
Jun 9, 2026
Hyman Steven
Director
AWARD30,000 sh
Jun 9, 2026
Vitale Nancy
Director
AWARD30,000 sh
Jun 9, 2026
SCANGOS GEORGE A
Director
AWARD30,000 sh

Earnings setup

Estimates
Nov 10
reports in 14 days
−$0.42
EPS estimate, this quarter
+12%
estimate change, 90 days
3↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.42-$0.80–-$0.28+0.0%$6.3M
Next Q-$0.40-$0.90–-$0.08+0.0%$8.1M
Current FY-$1.70-$2.62–-$1.24+0.0%$20.3M
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Voyager Therapeutics promoted Robin Swartz from COO/CBO to President, effective October 20, 2026, with a plan for her…
8-K — Impact 3/10
Aug 6, 2026 Earnings
Voyager Reports Second Quarter 2026 Financial and Operating Results
- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -
Jul 13, 2026 SEC
Voyager Therapeutics presented favorable GLP toxicology data for VY1706, its tau-silencing gene therapy for…
8-K — Impact 6/10
Jun 30, 2026 Inst.
MILLENNIUM MANAGEMENT LLC — ADD
4,442,951 shares ($15.6M)
Jun 30, 2026 Inst.
GEODE CAPITAL MANAGEMENT, LLC — ADD
1,330,492 shares ($4.7M)
Jun 9, 2026 Insider
PIERCE GLENN was granted 30,000 shares
Director
Jun 9, 2026 Insider
Colon Grace was granted 30,000 shares
Director
Jun 9, 2026 Insider
GERAGHTY JAMES A was granted 30,000 shares
Director
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
VYGR Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Aug 6, 2026
Earnings
Voyager Reports Second Quarter 2026 Financial and Operating Results
- VY7523 clinical data and VY1706 clinical entry, both in Alzheimer’s, expected Q4 2026 -
Aug 4, 2026
Earnings date
VYGR Q2 2026 Earnings Scheduled — 2026-08-04
Jul 30, 2026
Earnings date
VYGR Q2 2026 Earnings Scheduled — 2026-07-30
Jun 29, 2026
Press release
Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026
LEXINGTON, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging…
Jun 11, 2026
Press release
Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference
LEXINGTON, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging…

SecBot reports

7 filings · 2 press releases · 2 bullish · 2 bearish · 3 neutral
All VYGR filing & press-release reports (9)